Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Revenue (2023 - 2025)

Kura Oncology (KURA) has disclosed Revenue for 3 consecutive years, with $17.3 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 4401.74% to $17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.5 million through Dec 2025, up 4268.13% year-over-year, with the annual reading at $67.5 million for FY2025, 25.24% up from the prior year.
  • Revenue for Q4 2025 was $17.3 million at Kura Oncology, down from $20.8 million in the prior quarter.
  • The five-year high for Revenue was $20.8 million in Q3 2025, with the low at -$412000.0 in Q3 2024.
  • Average Revenue over 3 years is $5.4 million, with a median of -$390500.0 recorded in 2023.
  • The sharpest move saw Revenue decreased 9.34% in 2024, then soared 5136.41% in 2025.
  • Over 3 years, Revenue stood at -$394000.0 in 2023, then decreased by 2.28% to -$403000.0 in 2024, then surged by 4401.74% to $17.3 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $17.3 million, $20.8 million, and $15.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.